Neovastat (Æ-941), an inhibitor of angiogenesis: Randomized phase I/II clinical trial results in patients with plaque psoriasis

Journal of the American Academy of Dermatology

Volumn 47, Issue 4, 2002, Pages 535-541

  Sauder, Daniel N ^a   DeKoven, Joel ^a   Champagne, Pierre ^b   Croteau, Daniel ^b   Dupont, Éric ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Les Laboratoires Æterna Inc 1405   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AE 941; ANGIOGENESIS INHIBITOR; VASCULOTROPIN; DERMATOLOGICAL AGENT; SHARK CARTILAGE EXTRACT AE 941; TISSUE EXTRACT;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FLATULENCE; GROWTH REGULATION; HUMAN; KERATINOCYTE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEOVASCULARIZATION (PATHOLOGY); PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM; VOMITING; AGED; DOSE RESPONSE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; TISSUE EXTRACTS; TREATMENT OUTCOME;

EID: 0036771851     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.124702     Document Type: Article

References (33)

1. Baker H, Wilkinson DS, editors. Psoriasis, textbook of dermatology. Vol 2. Oxford (UK): Blackwell Publishers; 1979.
2. Krueger JG. Pathogenic interactions of keratinocytes and T lymphocytes in psoriasis. In: Roenigk HH Jr, Mailbach HI, editors. Psoriasis. New York: Marcel Dekker; 1998. p. 315-27.
3. Nickoloff BJ. The cytokine network in psoriasis. Arch Dermatol 1991;127:871-84.
4. Ortonne JP. Recent developments in the understanding of the pathogenesis of psoriasis. Br J Dermatol 1999;140(Suppl 54):1-7.
5. Kruegger GG. Psoriasis: current concepts of its etiology and pathogenesis. In: Dobson RL, Thiers BH, editors. Year book of dermatology. Chicago: Medical Publishers; 1981. p. 13-70.
6. Bhushan M, McLaughlin B, Weiss JB, Griffiths CE. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 1999;141:1054-60.
7. Ryan TJ, Microcirculation in psoriasis, blood vessels, lymphatics and tissue fluid. Pharmacol Ther 1980;10:27-64.
8. Fitzpatrick TB, editor. Dermatologie clinique: atlas commenté. Paris: Arnette Blackwell; 1995. p. 506.
9. Braveman IM. Electron microscope studies of the microcirculation in psoriasis. J Invest Dermatol 1972;59:91-8.
10. Cliff S, Bedlow AJ, Stanton AWB, Mortimer PS. An in vivo study of the mycrolymphatics in psoriasis using fluorescence microlymphography. Br J Dermatol 1999;140:61-6.
11. Nickoloff B, Mitra SR, Varani J, Dixit MV, Polverini PJ. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 1994;144:820-8.
12. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-39.
13. Smyth AP, Rook SL, Detmar M, Robinson GS. Antisense oligonucleotides inhibit vascular endothelial growth factor/vascular permeability factor expression in normal human epidermal keratinocytes. J Invest Dermatol 1997;108:523-6.
14. Brem H, Folkman J. Inhibition of tumor angiogenesis mediated by cartilage. J Exp Med 1975;141:427-39.
15. Gingras D, Renaud A, Rousseau N, Béliveau R. Shark cartilage extracts as antiangiogenic agents: smart drinks or bitter pills? Cancer Metastasis Rev 2000;19:83-6.
16. Dupont É, Brazeau P, Juneau C, inventors. Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof. US patent 5,618,925. April 18, 1997.
17. Dupont É, Brazeau P, Juneau C. Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof. US patent 5,985,839. Nov 16, 1999.
18. Dupont É, Brazeau P, Juneau C, Maes DH, Merenus K. Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic, and anti-tumoral activities; process of making, method of using and compositions thereof. US pateǹt 6,025,334. Feb 15, 2000.
19. Dupont É, Brazeau P, Juneau C, Maes DH, Merenus K. Methods of using extracts of shark cartilage. US patent 6,028,118. Feb 22, 2000.
20. , Dupont É, Falardeau P, Mousa SA, Dimitriadou V, Pepin M-C, Alaoui-Jamali M. Antiangiogenic and antimetastatic properties of Æ-941, an orally active extract derived from cartilage tissue. Clin Exp Metastasis 2002;19:145-53.
21. Gingras D, Renaud A, Mousseau N, Beaulieu E, Kachra Z, Béliveau R. Matrix proteinase inhibition by Æ-941, a multifunctional antiangiogenic compound. Anticancer Res 2001;21:145-55.
22. Dupont É, Savard PE, Jourdain C, Juneau C, Thibodeau A, Ross N, et al. Antiangiogenic properties of a novel shark cartilage extract: potential role in the treatment of psoriasis. J Cutan Med Surg 1998;2:146-52.
23. Dupont É, Wang B, Shivji G, Zhuang L, Dimitriadou V, Falardeau P, et al. Modulation of the immune response by Æ-941, a novel antiangiogenic agent. J Cutan Med Surg In press.
24. Evans WK, Latreille J, Batist G, Falardeau P, Champagne P, Rivière M, et al. Æ-941, an inhibitor of angiogenesis: rationale for development in combination with induction chemotherapy/radiotherapy in patients with non-small-cell lung cancer (NSCLC). Presented at The European Cancer Conference (ECCO-10), Vienna, Austria, Sept 12-16, 1999.
25. Dupont É, Alaoui Jamali M, Wang T, Doillon C, Ross N, Thibodeau A, et al. Angiostatic and antitumoral activity of Æ-941 (Æ-941), a molecular fraction derived from shark cartilage. Presented at American Association for Cancer Research, San Diego, Calif, April 12-16, 1997.
26. , Fredriksson T, Petterson V. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978;157:238-42.
27. Norris DA, Travers JB, Leung DYM. Lymphocyte activation in the pathogenesis of psoriasis. J Invest Dermatol 1997;109:1-4.
28. Folkman J, Brem H. Angiogenesis and inflammation. In: Gallin JI, Goldstein IM, Snyderman R, editors. Inflammation: basic principies and clinical correlates. New York: Raven Press; 1992. p. 821-39.
29. Folkman J, Li W, Casey R. Inflammation and angiogenesis. In: Melchers F, et al, editors. Progress in immunology. Berlin: Springer-Verlag; 1989, p. 761-4.
30. Karasek MA. Progress in our understanding of the biology of psoriasis. Cutis 1999;84:319-22.
31. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. FASEB J 1997;11:457-65.
32. Creamer D, Allen MH, Sousa EA, Poston R, Barker JN. Localization of endothelial proliferation of microvascular expansion in active plaque psoriasis. Br J Dermatol 1997;136:859-65.
33. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.